Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.

Breast (Edinburgh, Scotland)·2026
Same author

Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer.

World journal of oncology·2026
Same author

Biomarker use in predicting transcranial direct-current stimulation (tDCS) response: a systematic scoping review.

Frontiers in psychiatry·2026
Same author

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with <i>PIK3CA</i>-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.

Cancers·2026
Same author

Priority European strategies for sustainable access to high-quality genetic counselling in cancer: A Delphi study.

European journal of human genetics : EJHG·2026
Same author

Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma.

Frontiers in immunology·2025
Same journal

Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery.

Medical oncology (Northwood, London, England)·2026
Same journal

Expedited regulatory approval pathways for novel oncology drugs.

Medical oncology (Northwood, London, England)·2026
Same journal

Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.

Medical oncology (Northwood, London, England)·2026
Same journal

DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.

Medical oncology (Northwood, London, England)·2026
Same journal

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control.

Medical oncology (Northwood, London, England)·2026
Same journal

Unraveling the link between genomic instability and tumor immune evasion in oral squamous cell carcinoma: Role of CBMN assay and emerging perspectives.

Medical oncology (Northwood, London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Chemotherapy in clear cell sarcoma.

Robin L Jones1, Anastasia Constantinidou, Khin Thway

  • 1Royal Marsden Hospital, London, UK. ROBIN.JONES@doctors.org.uk

Medical Oncology (Northwood, London, England)
|April 15, 2010
PubMed
Summary
This summary is machine-generated.

Palliative chemotherapy shows minimal effectiveness for clear cell sarcoma (a rare cancer). Response rates were low, with a median progression-free survival of only 11 weeks in this study.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats
06:32

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

Related Experiment Videos

Last Updated: Jun 13, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats
06:32

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

Area of Science:

  • Oncology
  • Medical Oncology
  • Sarcoma Research

Background:

  • Clear cell sarcoma is a rare type of translocation-related sarcoma.
  • Limited data exists on the efficacy of palliative chemotherapy for clear cell sarcoma.
  • Understanding treatment response and survival is crucial for this rare cancer.

Purpose of the Study:

  • To evaluate the response rate and progression-free survival in clear cell sarcoma patients receiving palliative chemotherapy.
  • To establish a benchmark for treatment outcomes in clear cell sarcoma.
  • To inform the development of novel therapeutic agents for this subtype.

Main Methods:

  • Retrospective analysis of prospectively maintained databases from two referral centers.
  • Inclusion of clear cell sarcoma patients treated with first-line palliative chemotherapy.
  • Data collection on patient demographics, response rates, progression-free survival, and overall survival.

Main Results:

  • Twenty-four patients received first-line chemotherapy; 4% partial response, 38% stable disease, 58% progression.
  • Median progression-free survival was 11 weeks; median overall survival was 39 weeks.
  • Subsequent lines of chemotherapy demonstrated minimal activity, with high progression rates.

Conclusions:

  • Conventional chemotherapy exhibits limited activity in clear cell sarcoma.
  • The observed low response rate and short progression-free survival highlight the need for novel treatment strategies.
  • These findings provide essential reference data for future clinical trials evaluating new agents in clear cell sarcoma.